Boehringer Ingelheim is a research-driven company operating worldwide under two divisions: Human Pharmaceuticals and Animal Healthcare. In oncology, Boehringer Ingelheim is mainly focused on three areas: angiogenesis inhibition, EGFR inhibition and cell cycle kinase inhibition.
Support authors and subscribe to content
This is premium stuff. Subscribe to read the entire article.